HMR Lignans for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

HMR Lignans for Health & Longevity

Created on 08/04/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

HMR lignans from Norway spruce convert into enterolactone and raise blood levels at low milligram doses. Human evidence is narrow: one small industry-supported study found fewer postmenopausal hot flashes at 72 mg daily. Short-term safety looks favorable. Broader disease claims rest on enterolactone population data, not HMR outcome trials. Best framed as an efficient enterolactone raiser and candidate hot-flash option. (Full Review)

Protocol

Daily dose
36–72 mg/day 7-HMR
As HMRlignan potassium acetate co-crystal; hot-flash reduction at 72 mg/day
Form
Standardized spruce extract
Norway spruce knot; often ≥90% 7-HMR co-crystal (HMRlignan-type)
Timing
Once daily with a meal
Split dosing optional; start 36 mg/day if frail, polypharmacy, or low body weight
Time to effect
Hot flashes
~8 weeks
Symptom diary changes assessed over 8 weeks at 72 mg/day
Enterolactone rise
Within days
Parent 7-HMR peaks near 1 hour; enterolactone over many hours

Benefits

Contraindications
  • Pregnancy and lactation
  • Active estrogen-receptor–positive breast or gynecologic cancers without oncology approval
  • Children and adolescents
  • Known allergy to spruce/pine-derived materials
    •
Key Interactions
  • Selective estrogen-receptor modulators and aromatase inhibitors (tamoxifen, raloxifene, anastrozole, letrozole, exemestane)
  • Systemic hormone therapy and hormonal contraceptives
  • Antibiotics and major microbiome disruptors
  • Other phytoestrogens and high-lignan foods (soy isoflavones, flax SDG, red clover, hop extracts)
  • Anticoagulants / antiplatelets (warfarin, clopidogrel; aspirin, high-dose NSAIDs)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild estrogenic / antiestrogenic tissue effects; gastrointestinal intolerance
    •
  • Speculative: Theoretical concerns in hormone-sensitive cancer; uncertain long-term high-dose safety in humans
    •

Monitoring

Marker Target Why
Enterolactone (plasma/serum) Higher within lab reference; no universal clinical cut-off Confirms conversion of 7-HMR to enterolactone
Estradiol / FSH (postmenopause) Age- and goal-dependent; conventional postmenopausal estradiol typically <30 pg/mL Context for phytoestrogen use and assessment of hot-flash causes
High-sensitivity CRP Often <1.0 mg/L functional target General inflammatory tone
Fasting glucose / HbA1c Glucose ~70–90 mg/dL; HbA1c often <5.5% functional aim Metabolic context given preclinical HMR data
Comprehensive metabolic panel (ALT, AST, creatinine, eGFR) Within lab reference; eGFR ≥90 mL/min/1.73 m² preferred Baseline organ function before long-term polyphenol supplement

Cadence: Symptom diaries at 4 and 8 weeks, then every 3–6 months if continued; safety labs every 6–12 months in long-term multi-supplement users or those with comorbidities; enterolactone (if used) after ≥4 weeks on a stable dose

Qualitative Assessment

  • Hot flash frequency, severity, and night sweats
  • Sleep continuity and next-day energy
  • Digestive comfort after dosing
  • Subjective joint comfort or recovery (exploratory only)
  • Overall sense of hormonal stability (libido, mood, cycle regularity if pre-/perimenopausal)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.